Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Zoetis Inc. Executive Vice President Roxanne Lagano reported equity award activity involving restricted stock units and common shares. On February 19, 2026, she acquired 750.4257 restricted stock units through an exercise or conversion, resulting in 1,500 restricted stock units directly held after the transaction.
On the same date, she acquired 750 shares of Zoetis common stock upon vesting and settlement of restricted stock units, bringing her directly held common stock to 15,890 shares before tax withholding. To satisfy tax obligations, 258 shares of common stock were disposed of at $127.28 per share in a tax-withholding transaction, leaving 15,632 common shares held directly.
In addition to common shares, Lagano holds 3,664 restricted stock units and 545 restricted stock units from separate awards, each RSU representing a contingent right to receive one share of Zoetis common stock, with vesting generally in one-third installments on the first, second and third anniversaries of the applicable grant dates. She also indirectly holds 833.684 common stock equivalents through the Zoetis Inc. Savings Plan, a 401(k) plan, as of December 31, 2025.
Zoetis Inc. Executive Vice President Kevin Esch reported equity transactions tied to his compensation. On February 19, 2026, restricted stock units were exercised into 102 shares of Zoetis common stock at a stated price of $0.00 per share, reflecting vesting of RSUs. To cover tax obligations, 35 shares of common stock were disposed of at $127.28 per share through share withholding, a non‑open‑market transaction.
Following these transactions, Esch directly held 394 shares of Zoetis common stock and several blocks of RSUs, including 4,026, 775.5724 and 44 RSUs that each represent a contingent right to receive one share upon vesting. Footnotes explain that most RSU awards vest in three equal annual installments on the first, second and third anniversaries of their grant dates, subject to his continued service and certain earlier‑vesting events. He also indirectly held 122.9323 common stock equivalents through the Zoetis Savings Plan (401(k)) as of December 31, 2025.
Zoetis Inc. Executive Vice President Jamie Brannan reported equity-related transactions on February 19, 2026. Brannan acquired 1,204.0741 restricted stock units through an exercise or conversion and received 1,204 shares of common stock upon vesting and settlement of RSUs, each representing one Zoetis share.
To cover tax obligations, 566 common shares were disposed of at $127.28 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Brannan directly held 3,290 common shares, plus additional RSU holdings and 445 common stock equivalents indirectly through the UK Share Ownership Plan.
Zoetis Inc. Executive Vice President Keith Sarbaugh reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 19, 2026, RSUs converted into 386 shares of Zoetis common stock, increasing his directly held common shares.
On the same date, 154 common shares were disposed of at $127.28 per share to satisfy tax withholding obligations, a non‑open‑market transaction. After these transactions, Sarbaugh directly owned 2,342 Zoetis common shares and held multiple RSU awards under the Zoetis Amended and Restated 2013 Equity and Incentive Plan, which generally vest in three equal installments on the first, second, and third anniversaries of their grant dates.
Zoetis Inc. Executive Vice President Rimma Driscoll reported equity transactions involving restricted stock units and common shares. On February 19, 2026, she acquired 454.6338 restricted stock units through an exercise or conversion of derivative securities and received 454 shares of Zoetis common stock at a price of $0.00 per share upon RSU vesting and settlement.
On the same date, 179 shares of common stock were disposed of at $127.28 per share to satisfy tax withholding obligations related to these awards. After these transactions, she held 5,715 shares of common stock directly. Footnotes state that each RSU represents a right to receive one share of Zoetis common stock, generally vesting in one-third increments on the first, second, and third anniversaries of the respective grant dates, subject to continued service and certain earlier vesting events.
Zoetis Inc. Executive Vice President Ferran Astorga Jeannette reported equity award activity involving restricted stock units (RSUs) and common shares. On February 19, 2026, RSUs covering 431.6543 units were exercised or converted, resulting in the acquisition of 431 shares of Zoetis common stock.
On the same date, 190 common shares were disposed of at $127.28 per share in a tax-withholding transaction to satisfy tax obligations associated with the equity award, rather than an open-market sale. After these transactions, the reporting person directly held 1,684 common shares and RSU holdings of 2,197 and 207 units in separate grants, each RSU representing a contingent right to receive one share of common stock subject to multi-year vesting schedules and continued service conditions.
Zoetis Inc. director Sanjay Khosla reported equity award activity involving restricted and deferred stock units. On February 19, 2026, 1,619.3325 restricted stock units were exercised and converted into an equal number of deferred stock units at no cash cost.
These deferred stock units are fully vested, accrue dividend equivalents, and each unit corresponds to one share of Zoetis common stock. Following the grant, Khosla directly held 11,620.8453 deferred stock units and 1,936 restricted stock units. Deferred units will be paid in Zoetis shares after his board service ends or upon specified change-in-control or termination events.
Zoetis Inc. director Antoinette Renee Leatherberry reported equity award activity involving restricted stock units (RSUs) and common stock. On February 19, 2026, she exercised or converted RSUs into 1,619 shares of Zoetis common stock, with each RSU delivering one share upon vesting.
The filing shows 406 shares of common stock were disposed of to Zoetis Inc. in exchange for cash based on the closing share price of $127.28 as of the vesting date. After these transactions, she directly owned 5,280 shares of Zoetis common stock and held 1,936 RSUs that represent contingent rights to receive additional shares, subject to vesting conditions.
Zoetis Inc. director Paul Bisaro acquired common stock through the vesting and settlement of restricted stock units. On February 19, 2026, 1,619.3325 RSUs were exercised or converted, resulting in the acquisition of 1,619 shares of Zoetis common stock at a stated price of $0.00 per share.
After these transactions, he directly owned 25,862 shares of Zoetis common stock. He also held 1,936 restricted stock units, each representing a contingent right to receive one share of Zoetis common stock, which are scheduled to vest and settle on the first anniversary of their grant date, February 18, 2026, subject to continued service and certain earlier vesting events.
Zoetis Inc. director Frank A. D'Amelio reported equity award and deferral activity involving company stock units. On February 19, 2026, previously granted restricted stock units were converted into 1,619.3325 deferred stock units (DSUs) under a voluntary deferral. After this grant and related accruals, he directly holds 11,620.8453 DSUs, each representing one share of Zoetis common stock to be settled after his board service ends. He also directly holds 1,936 restricted stock units (RSUs), which are scheduled to vest and be settled in shares on the first anniversary of their grant, February 18, 2026, subject to continued service and certain earlier-vesting events.